

Amgen's Oncology Pipeline: Investigating Next-Generation Medicines

GI CANCERS

Target: **FGFR2b**

Bemarituzumab
Monoclonal antibody
G/GEJC Phase 3

Target: **EGFR**

Panitumumab
Monoclonal antibody
CRC Phase 3

Target: **KRAS^{G12C}**

Sotorasib
Small molecule
CRC Phase 3

Target: **PRMT5**

AMG 193
Small molecule
Biliary tract cancer, Pancreatic cancer Phase 1

LUNG CANCERS

Target: **KRAS^{G12C}**

Sotorasib
Small molecule
NSCLC Phase 3

Target: **PRMT5**

AMG 193
Small molecule
NSCLC Phase 1

Target: **CLDN6**

AMG 794
BITE* molecule
NSCLC Phase 1

PROSTATE CANCERS

Target: **STEAPI**

Xaluritamig (AMG 509)
XmAb* platform
mCRPC Phase 1

Target: **DLL3**

Tarlatamab
BITE* molecule
NEPC Phase 1b

OTHER SOLID TUMORS

Target: **Thrombopoiesis stimulator for CIT**

Romiplostim
Protein/peptibody
Various solid tumors Phase 3

Target: **PD-1**

ABP 206*
Monoclonal antibody
Melanoma Phase 3

Target: **FGFR2b**

Bemarituzumab
Monoclonal antibody
Various solid tumors Phase 2

Target: **KRAS^{G12C}**

Sotorasib
Small molecule
Various solid tumors Phase 2

HEMATOLOGY

Target: **CD19**

Blinatumomab
BITE* molecule
ALL Phase 3

Target: **Proteasome**

Carfilzomib
Small molecule
Multiple myeloma Phase 3
Pediatric ALL Phase 2

Target: **Complement C5**

ABP 959*
Monoclonal antibody
PNH Phase 3

Target: **MCL-1**

AMG 176
Small molecule
AML/MDS Phase 1

SCAN TO DOWNLOAD



Oncology pipeline mural



Clinical trials brochure

This information reflects public disclosures as of Oct 26, 2023. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. The descriptions herein contain forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

ALL = Acute lymphoblastic leukemia; **AML** = Acute myeloid leukemia; **BITE*** = Bispecific T-cell engager; **CAR** = Chimeric antigen receptor; **CIT** = Chemotherapy-induced thrombocytopenia; **CRC** = Colorectal cancer; **G/GEJC** = Gastric or gastroesophageal junction cancer; **mCRPC** = Metastatic castration-resistant prostate cancer; **MDS** = Myelodysplastic syndrome; **NEPC** = Neuroendocrine prostate cancer; **NSCLC** = Non-small cell lung cancer; **PNH** = Paroxysmal nocturnal hemoglobinuria; **SCLC** = Small cell lung cancer.

* The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference indications with scientific justification. XmAb* is a registered trademark of Xencor.

© 2023 Amgen Inc. All rights reserved. USA-OCF-82325

AMGEN[®]

Advancing All Angles of Care